A share price of Myriad Genetics, Inc. [MYGN] is currently trading at $27.03, down -1.31%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MYGN shares have gain 1.81% over the last week, with a monthly amount drifted -4.59%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Myriad Genetics, Inc. [NASDAQ: MYGN] stock has seen the most recent analyst activity on September 19, 2024, when Morgan Stanley initiated its Equal-Weight rating and assigned the stock a price target of $32. Previously, Wells Fargo started tracking the stock with Overweight rating on August 28, 2024, and set its price target to $35. On June 27, 2024, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $29 on the stock. Leerink Partners upgraded its rating to a Outperform and raised its price target to $35 on May 08, 2024. In a note dated December 19, 2023, Wells Fargo initiated an Equal Weight rating and provided a target price of $20 on this stock.
Myriad Genetics, Inc. experienced fluctuations in its stock price throughout the past year between $13.82 and $29.30. Currently, Wall Street analysts expect the stock to reach $28.29 within the next 12 months. Myriad Genetics, Inc. [NASDAQ: MYGN] shares were valued at $27.03 at the most recent close of the market. An investor can expect a potential return of 4.66% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
Trailing Twelve Months sales for Myriad Genetics, Inc. [NASDAQ:MYGN] were 802.20M which represents 15.26% growth. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.47%, and Net Profit Margin reading is -0.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.25 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.74 points at the first support level, and at 26.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.44, and for the 2nd resistance point, it is at 27.84.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Myriad Genetics, Inc. [NASDAQ:MYGN] is 1.96. As well, the Quick Ratio is 1.78, while the Cash Ratio is 0.36. Considering the valuation of this stock, the price to sales ratio is 3.06, the price to book ratio is 3.32.
Transactions by insiders
Recent insider trading involved Ancona Margaret, Officer, that happened on Aug 21 ’24 when 11538.0 shares were purchased. President and CEO, DIAZ PAUL J completed a deal on Sep 11 ’24 to sell 15000.0 shares. Meanwhile, Chief Scientific Officer Muzzey Dale sold 2100.0 shares on Sep 11 ’24.
